
Innovations for Heart and Vessels sp. z o.o.
Other research and experimental development on natural sciences and engineering
Overview
Innovations for Heart and Vessels develops InFlow transcatheter aortic valves for TAVI, using biological porcine tissue or biocompatible polymers. The valves offer high biocompatibility, a low risk of calcification and enhanced durability through a proprietary component-joining method, supported by an atraumatic self-positioning delivery system.
Financials
Revenue history (in k)
From the notes
| Profit allocation | No decision | |
| Capital expenditure | $2,220,654 | |
| Planned capital expenditure (next year) | $2,762,431 | |
| Revenue structure | Sprzedaż produktów i usług w kraju | |
| R&D costs | $2,505,531 | |
| Management board pay | $47,966 |
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 58 days late). 2 of 6 audited by a statutory auditor.
- 202524/06/2026
- 202424/06/2025
- 202319/06/2024
- 202204/07/2023
- 202111/09/2022
- 202027/02/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

Publication: long-term bio-functional performance of a novel self-positioning biological TAVI aortic valve system in the ovine model – Cardiology Journal

Presentation: Innovations for Heart and Vessels – introduction to the InFlow project

Video: InFlow TAVI project – short presentation

Publication: temporal, biomechanical evaluation of a novel transcatheter polymeric aortic valve in the ovine model – Frontiers in Cardiovascular Medicine
Industry
Offer
- Biological aortic valves
- Polymeric aortic valves
- Valve implantation systems
- Preclinical testing
Websites
The site is available in: Polish and English.
- i4hv.comHome – I4HV – innovations for heart & vesselsWordPressGoogle AnalyticsGoogle Tag ManagerYoast SEOPPolylangCloudflare
Job offers
The company has its own careers page: i4hv.com/careers.
Authorized Representatives
Manner of representation
In the case of a multi-member management board, declarations of will, signing documents on behalf of the company and granting powers of attorney require the joint action of two members of the management board, including in every case the President of the Management Board, if appointed, and in the case of a one-person management board, the company is represented independently by the President of the Management Board.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Paweł Eugeniusz Buszman age 65 | 268 | $7,239.33 | 40.8537% |
Fundacja Rodzinna Pro Benefis Familiae | 195 | $5,267.42 | 29.7256% |
Others | 193 | $5,213.40 | 29.4207% |
Beneficial owners
| Person | Rights |
|---|---|
Subsidiaries
| Name | Share value | Stake | ||
|---|---|---|---|---|
Graftflow sp. z o.o. | 1,269.58 USD | 63.0872% |
Sanctions and PEP
Sanctions
No matches (EU, UN, US, UK, MSWiA, World Bank)
PEP
No matches
Bank accounts
Registered as a VAT taxpayer on 2019-07-23.
49 1600 1462 1717 7107 8000 0002
13 1600 1055 1773 7458 4000 0001
56 1600 1055 1773 7458 4000 0003
Debt
No entries in the National Debtors Register (KRZ).
Public aid
10 public aid cases recorded, with a total value of $17,784,105.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| May 14, 2026 | De minimis aid (in accordance with Commission Regulation 2023/2831) | $7,563$7,563 | Akademia Śląska | |
| Jun 27, 2025 | Aid for research and development projects: experimental development | $6.2M$6,216,954 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości | |
| Jun 27, 2025 | Regional investment aid | $1.3M$1,268,747 | Prezes Polskiej Agencji Rozwoju Przedsiębiorczości |
European Funds
4 projects co-financed from European Funds recorded, with total EU co-financing of $18,149,567.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2024-11-04 | Development of production technology and prototypes of polymer valve implants for the transcutaneous and minimally invasive treatment of valve defects | $7.5M$7,468,820 | European Funds for a Modern Economy | |
| 2024-05-01 | Development of a production technology and prototypes of biological valve implants for transcutaneous and minimally invasive treatment of valvular defects. | $8M$7,987,607 | European Funds for a Modern Economy | |
| 2024-03-01 | Polymer transcatheter aortic valve implants with a dedicated delivery system | $2.7M$2,678,785 | European Funds for a Modern Economy |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Medical Inventi S.A. | $386,209.84 | medicalinventi.pl | ||
| Forslab sp. z o.o. | $347,874.57 | forslab.eu | ||
| F.R.K. Intra-Cordis sp. z o.o. | $215,043.19 | intracordis.com.pl | ||
| Cleardent sp. z o.o. | $183,221.50 | cleardent.pl | ||
| Nano Prime sp. z o.o. | $167,485.01 | nano-prime.com | ||
| Integris Medical Polska sp. z o.o. | $159,033.76 | integrismedical.pl | ||
| Astend sp. z o.o. | $105,928.35 | astend.pl | ||
| Medinice S.A. | $93,169.26 | medinice.pl | ||
| Dental Nanotechnology S.A. | $36,471.58 | dentalnt.com | ||
| Biotreat Vascular sp. z o.o. | $20,270.13 | biotreatvascular.com |
Change history
| Date | Event | |
|---|---|---|
| 2024-06-13 | Share capital increase (44,500.00 PLN → 65,600.00 PLN) | |
| 2024-02-15 | Share capital increase (44,000.00 PLN → 44,500.00 PLN) | |
| 2023-06-02 | Share capital increase (42,700.00 PLN → 44,000.00 PLN) | |
| 2022-04-08 | Share capital increase (40,000.00 PLN → 42,700.00 PLN) | |
| 2022-02-18 | PKD change (Removed: 18 codes) |
FAQ
Last updated: 2026-06-24